Author

E. Jirovec

Institution: University of Helsinki

Observed institution: University of Helsinki

OpenAlex ID: A5045424077

Improving the cytotoxic response of tumor-infiltrating lymphocytes towards advanced stage ovarian cancer with an oncolytic adenovirus expressing a human vIL-2 cytokine

2023 · D. C. A. Quixabeira, E. Jirovec, et al. · Cancer Gene Therapy · 12

Boosting cytotoxicity of adoptive allogeneic NK cell therapy with an oncolytic adenovirus encoding a human vIL-2 cytokine for the treatment of human ovarian cancer

2023 · D. C. A. Quixabeira, S. Pakola, et al. · Cancer Gene Therapy · 11

48O Safety and efficacy of combined treatment with tumor infiltrating lymphocytes (TILs) and oncolytic adenovirus TILT-123 for patients with metastatic melanoma: Results from a phase I trial

2023 · T.J. Monberg, S. Pakola, et al. · Immuno-Oncology Technology · 2

6P Natural IgM and dyslipidemia enhance the efficacy of tumor necrosis factor and interleukin-2 encoding oncolytic adenovirus in solid tumors

2025 · J.H.A. Clubb, S.A. Pakola, et al. · Immuno-Oncology Technology · 1

264P Split-dose intravenous delivery of igrelimogene litadenorepvec enhances viral levels in blood and tumours compared with conventional intratumoral injection

2025 · S.A. Pakola, V. Cervera-Carrascon, et al. · Immuno-Oncology Technology

259P Intravenous oncolytic adenovirus encoding tumor necrosis factor and interleukin 2 with immunomodulatory metronomic cyclophosphamide in patients with advanced solid tumors

2025 · S.A. Pakola, K. Jalkanen, et al. · Immuno-Oncology Technology

5P Neutralizing antibodies as functional effectors and predictive biomarkers in oncolytic adenovirus therapy

2025 · V. Arias Illana, J.H.A. Clubb, et al. · Immuno-Oncology Technology

1203P Clinical correlations and long-term survival in PROTA: Platinum-resistant or refractory ovarian cancer treated with an oncolytic adenovirus encoding TNF and IL2 in combination with pembrolizumab

2025 · N. Ojala, J. Clubb, et al. · Annals of Oncology

1579P Fully intravenous split-dose administration of oncolytic adenovirus TILT-123 in advanced solid tumors

2025 · E. Jirovec, D.C.A. Quixabeira, et al. · Annals of Oncology

163P Effect of split intravenous dosing of oncolytic adenovirus TILT-123 on normal tissue versus tumor macrophages and virus bioavailability in patients with advanced solid tumors

2024 · E. Jirovec, D.C.A. Quixabeira, et al. · Immuno-Oncology Technology

127P Combining chemotherapy and checkpoint inhibitors with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine to treat pancreatic ductal adenocarcinoma

2024 · N. Ojala, S.A. Pakola, et al. · Immuno-Oncology Technology

1025P Fully intravenous delivery regimen of oncolytic adenovirus coding for TNFa and IL-2 (TILT-123) in patients with advanced solid cancers

2024 · S.A. Pakola, K. Jalkanen, et al. · Annals of Oncology

50P Enhancing TIL and NK cells adoptive therapies with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine for the treatment of human ovarian cancer

2022 · D.C.A. Quixabeira, S. Pakola, et al. · Immuno-Oncology Technology

Works count: 13

Citation count: 26

H-index: 2

I10-index: 2